Androgen Deprivation Therapy Toxicity and Management for Men Receiving Radiation Therapy
Author(s) -
M.E. Johnson,
Mark K. Buyyounouski
Publication year - 2012
Publication title -
prostate cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.377
H-Index - 11
eISSN - 2090-3111
pISSN - 2090-312X
DOI - 10.1155/2012/580306
Subject(s) - medicine , androgen deprivation therapy , prostate cancer , neurocognitive , radiation therapy , androgen , erectile dysfunction , enzalutamide , toxicity , oncology , intensive care medicine , cancer , psychiatry , hormone , androgen receptor , cognition
Androgen deprivation therapy is commonly used in combination with radiotherapy as part of the definitive treatment for men with clinically localized and locally advanced prostate cancer. Androgen deprivation has been associated with a wide range of iatrogenic effects impacting a variety of body systems including metabolic, musculoskeletal, cardiovascular, neurocognitive, and sexual. This review aims to provide the radiation oncology community with the knowledge to monitor and manage androgen deprivation therapy toxicity in an effort to provide the highest level of care for patients and to minimize the iatrogenic effects of androgen deprivation as much as possible.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom